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Abstract 
Chromosomal translocations involving 
chromosome bands 5q31-33 that contain the gene 
encoding the platelet-derived growth factor beta 
receptor (PDGFRB) are associated with a 
significant minority of patients with BCR/ABL1-
negative chronic myeloid neoplasms. To date, 
numerous PDGFRB fusion partners have been 
identified, with the vast majority being reported 
only in sporadic cases. Although PDGFRB fusions 
are rare, their identification is important in order to 
identify patients in whom targeted therapy with 
tyrosine kinase inhibitors is likely to be successful. 
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Included are reported patients with reciprocal 5q31-
5q33 translocations, with or without PDGFRB 
involvement as patients with rearrangements of this 
gene had translocations that appeared 
cytogenetically to involve bands from 5q31 to 
5q33. Therefore, in patients with reciprocal 
translocation involving chromosome band 5q31-33 
it is important to identify involvement of PDGFRB 
by molecular testing or by the use of dual color 
break-apart probes that allows detection of 
PDGFRB rearrangements before considering 
targeted therapy. 
Clinics and pathology 
Disease 
Myeloproliferative disorders (MPD) with 
eosinophilia (or chronic eosinophilic leukemia 
(CEL) and sporadic cases with acute myeloid 
leukemia (AML), B-cell acute lymphoblastic 
leukemia (ALL) or lymphoma. 
Phenotype/cell stem origin 
Phenotypically diverse myeloid neoplasms that 
include patients that have been categorized as: 
chronic eosinophilic leukemia (CEL)/ atypical 
chronic myeloid leukemia with eosinophilia in 4 
(Luciano et al., 1999; Rosati et al., 2006, Baxter et 
al., 2003, Li et al., 2011), chronic 
myeloproliferative disorder (MPD) in 2 (Darbyshire 
et al., 1987; Baxter et al., 2003), juvenile 
myelomonocytic leukemia (JMML) in 2, 1 of them 
congenital JMML (Grainger et al., 2002 Abraham 
et al., 2010), chronic myeloid leukemia (CML) in 1 
(Hild & Fonatsch.,1990), 
myelodysplastic/myeloproliferative disease in 1 
(Wilkinson et al., 2003), refractory anemia with 
excess of blasts in 1 (RAEB) (Xu et al., 2010) and 
acute myeloid leukemia in 3 (Baxter et al., 2003; 
Kern et al., 2002; Shearer et al., 2010).  The 
remaining cases were lymphoid malignancies: 5 B-
cell ALL (Craig et al., 1990; Barriga et al., 1996; 
Coyaud et al., 2010; Safavi et al., 2015), 1 mantle 
cell lymphoma (MCL) (Le Baccon et al., 2001) and 
1 diffuse large B-cell lymphoma (DLBCL) (Le 
Baccon et al., 2001). 
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Figure 1.  Partial karyotypes with t(1;5)(q25;q33) (A). Fluorescence in situ hybridization with LSI 1p36/1q25 dual color probe 
(Vysis. Abott Molecular, US) showing the signal for 1q25 on der(1) chromosome (green signal) indicative of breakpoint distal to 
the probe (B).  Hybridization with LSI 1p36/1q25 dual color and Kreatechô PDGFRB Break (Leica Biosystems, US) probes 
revealed PDGFRB remains on der(5) and is not disrupted by the translocation (C) - Courtesy Adriana Zamecnikova. 
 
Epidemiology 
Male prevalence (12 males and 7 females) aged 0 to 
79 years (median age 21 years) and notably, 5 
patients were infants (1 male and 3 females) 
(Darbyshire et al., 1987; Wilkinson et al., 2003; 
Grainger et al., 2002; Abraham et al., 2010) (Table 
1). Because the phenotypes are different, it may be 
that genes involved in this/these disease(s) are not 
similar; PDE4DIP and PDFRGB were found 
involved in MPD with eosinophilia (see below). 
Clinics 
Patients typically present with myeloproliferative 
neoplasm with eosinophilia and a spectrum of 
morphologic presentations. Although eosinophilia 
is characteristic of myeloid neoplasms associated 
with PDGFRB rearrangement, marked eosinophilia 
is not an invariable feature and the clinical 
presentation is variable. Patients are typically male 
and while children are rarely affected with 
PDGFRB gene fusions, 6 out of 19 described 
patients with t(1;5)(q21-23;q31-33) were children 
aged 0 to 13 years. 
Prognosis 
One of the infants with MPD died 9 month after 
diagnosis and the other remains well on therapy 14 
months from diagnosis (Darbyshire et al., 1987). 
The infant with PDE4DIP/PDGFRB fusion had 
refractory and progressive disease, but after therapy 
with imatinib was started complete clinical and 
hematologic remission, as well as major 
cytogenetic response was achieved (Wilkinson et 
al., 2003). 1 infant with JMML received autologous 
stem cell transplantation after initial cytoreductive 
therapy failed to control the disease and is alive at 
10 years in full cytogenetic remission (Grainger et 
al., 2002) and 1 with congenital JMML is alive 16+ 
months on imatinib therapy (Abraham et al., 2010). 
The 8-year-old male with CEL and 
TPM3/PDGFRB fusion had rapid hematologic 
response and reduction of TPM3/PDGFRB 
transcripts after targeted therapy with imatinib (Li 
et al., 2011). The 21-years old patient with CEL 
obtained complete hematologic and major 
cytogenetic response after two years of interferon 
therapy and is alive 7 years from diagnosis 
(Luciano et al., 1999).  The other 21-years old male 
with CEL and confirmed TPM3/PDGFRB fusion 
received interferon therapy for 10 years resulting in 
major cytogenetic response and after continuing 
with imatinib he achieved hematological, 
cytogenetic and FISH remission (Rosati et al., 
2006). 
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Ref Genes Sex/age Disease Karyotype Survival 
1 PDE4DIP/PDGFRB F/0 MPD 46,XX,t(1;5)(q23;q33) 
19+ months, on 
imatinib 
2 TPM3/PDGFRB M/21 CES 46,XY,t(1;5)(q21;q33) 
Therapy with 
 interferon and 
imatinib, alive 
10+ years  
3 TPM3/PDGFRB M/8 CEL t(1;5)(q21;q33) 




















M/0 JMML t(1;5)(q21;q33) 








t(1;5)(q21;q31)   




9 ? F/0 JMML 46,XX,t(1;5)(q21;q33) 
Alive after 
BMT 10+ years 









12 ? M/51 B-ALL 46,XY,t(1;5)(q21;q31),del(9)(p12)   
13 ? F/22 B-ALL 46,XX,t(1;5)(q21;q32)/42-48,idem,+8/48,idem,+der(5)t(1;5),+21   







15 ? F/0 MPD 46,XX,t(1;5)(q23;q33) 
died 9 month 
after diagnosis  
16 ? M/0 MPD 46,XY,t(1;5)(q23;q33) 
Alive 14+ 
months  
17 ? M/21 CEL 46,XY,t(1;5)(q23;q31) 
interferon 
therapy, alive 
7+ years  




19 ? M/13 B-ALL 46,XY,t(1;5)(q23;q33) 
Relapse after 3 
months; CNS 
relapse on day 
+ 106 after 
BMT and died. 
Abbreviations: M, male; F, female; MPD, Myeloproliferative disorder; CES; Chronic eosinophilic syndrome; CEL; Chronic 
eosinophilic leukemia; aCML, Atypical chronic myeloid leukemia; JMML, Juvenile myelomonocytic leukemia; MDS, 
myelodyslastic syndrome; AML; Acute myeloid leukemia; CML, Chronic myeloid leukemia; BMT, bone  marrow transplantation; 
B-ALL, B-cell Acute lymphoblastic  leukemia; DLBCL, Diffuse large B-cell  lymphoma; LN, lymph node;, RAEB, Refractory 
anemia with excess of blasts.  
1. Wilkinson et al., 2003; 2. Rosati et al., 2006; 3. Li et al., 2011; 4-5,7.  Baxter et al., 2003; 6. Abraham et al., 2010; 8. Hild & 
Fonatsch.,1990; 9.  Grainger et al., 2002; 10. Kern et al., 2002; 11. Shearer et al., 2010; 12.  Coyaud et al., 2010; 13. Safavi et 
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The 13-years-old boy with high-risk early pre-B 
ALL underwent allogeneic bone marrow 
transplantation after relapse but after a short second 
remission he had a central nervous system relapse 
and died (Barriga et al., 1996).   
From these data, it appears that patients with 
t(1;5)(q21-23;q31-33) and PDGFRB rearrangement 




Sole anomaly in 12 out of 19 described patients, 
found in association with t(9;22)(q34;q11) in a 
sideline in CML (Hild & Fonatsch.,1990), 
t(8;21)(q22;q22) in AML (Kern et al., 2002), 
del(9)(p12)  in ALL (Coyaud et al., 2010), 
inv(3)(q21q26)/ -7 in AML (Shearer et al., 2010) 
and complex karyotypes in 3 patients  (Le Baccon 
et al., 2001; Xu et al., 2010; Safavi et al., 2015). 
Genes involved and 
proteins 
Note 
Involvement of PDGFRB was demonstrated in 
several patients with t(1;5)(q21-23;q31-33) and 
there has been two identified PDGFRB partner 
genes located at 1q21,  PDE4DIP (Wilkinson et al., 
2003) and TPM3 (Rosati et al., 2006; Li et al., 
2011).  
It is also possible that other genes from the 5q31-
q33 region such as TCOF1, CSF1R and CDX1 are 
potential translocation targets as well as IL3, IL5 
and CSF2 (GM-CSF) (cytokines involved in 
eosinophilopoiesis) may be dysregulated in the 
translocation process, at least in some patients. 
PDE4DIP (phosphodiesterase 4D 
interacting protein (myomegalin)) 
Location 1q21.1 
Protein 
PDE4DIP codes for a protein called myomegalin; 
interacts with the cyclic nucleotide 
phosphodiesterase PDE4D; there are at least 2 
major isoforms of myomegalin in humans 
(KIAA0454 and KIAA0477), encoding N and C 
termini (Verde et al., 2001; Wilkinson et al., 2003); 
myomegalin encodes several putative 
oligomerization domains capable of activating 
PDGFRB. They include a leucine zipper (LZ) 
domain and several coiled-coil structures. 





Member of the tropomyosin family of actin-binding 
proteins that are dimers of coiled coil proteins; 
binds and to actin filaments in muscle and non-
muscle cells; mediates myosin-actin response to 
calcium ions in skeletal muscles and regulates the 
access to other actin-binding proteins; non-muscle 
isoform is found in cytoskeletal microfilaments 
(Rosati et al., 2006). 
PDGFRB (platelet-derived growth 
factor receptor, beta polypeptide) 
Location 5q32 
Protein 
PDGFRB is the receptor for PDGFB (platelet-
derived growth factor-b); Ig like, transmembrane 
and tyrosine kinase domains; membrane tyrosine 
kinase; can homodimerize; activated in response to 
ligand binding and receptor dimerization. 




PDE4DIP/PDGFRB. 5' PDE4DIP - 3' PDGFRB; 
PDE4DIP (KIAA0477 isoform) fuses in frame 
PDGFRB exon 11. The reciprocal PDGFRB-
PDE4DIP is not expressed. 
Description 
TPM3/PDGFRB. TPM3 fused exon 7 with exon 11 
of the PDGFRB. A reciprocal fusion of exon 10 of 




The first 905 amino acids of PDE4DIP, including 
the coiled-coil domains are fused to the 
transmembrane and the tyrosine kinase domains of 
PDGFRB. 
Oncogenesis 
Hematolymphoid neoplasms associated with 
PDGFRB gene fusions are infrequent and can be 
observed in a wide range of hematological 
malignancies including myeloproliferative 
neoplasms with eosinophilia, atypical CML, Ph-like 
acute lymphoblastic leukemia and AML. 
Genetically they are equally heterogeneous with at 
least 30 fusion genes having been described, 
resulting from the formation of abnormal fusion 
genes that encode constitutively activated tyrosine 
kinases. While several PDGFRB partner genes 
remain to be characterized, constitutive activation 
of protein tyrosine kinases is a common feature of 
neoplasms with fusion genes derived from 
PDGFRB, triggering downstream signaling, but 
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importantly they can be successfully targeted by 
tyrosine kinase inhibitors such as imatinib. 
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